Search Results - Watmuff, Maura

  • Showing 1 - 3 results of 3
Refine Results
  1. 1
    First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1)

    First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1) by Postel-Vinay, Sophie, Lam, Vincent K, Ros, Willeke, Bauer, Todd M, Hansen, Aaron R, Cho, Daniel C, Stephen Hodi, F, Schellens, Jan H M, Litton, Jennifer K, Aspeslagh, Sandrine, Autio, Karen A, Opdam, Frans L, McKean, Meredith, Somaiah, Neeta, Champiat, Stephane, Altan, Mehmet, Spreafico, Anna, Rahma, Osama, Paul, Elaine M, Ahlers, Christoph M, Zhou, Helen, Struemper, Herbert, Gorman, Shelby A, Watmuff, Maura, Yablonski, Kaitlin M, Yanamandra, Niranjan, Chisamore, Michael J, Schmidt, Emmett V, Hoos, Axel, Marabelle, Aurelien, Weber, Jeffrey S, Heymach, John V

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  2. 2
    Abstract CT150: A first-in-human phase I study of the OX40 agonist GSK3174998 (GSK998) +/- pembrolizumab in patients (Pts) with selected advanced solid tumors (ENGAGE-1)

    Abstract CT150: A first-in-human phase I study of the OX40 agonist GSK3174998 (GSK998) +/- pembrolizumab in patients (Pts) with selected advanced solid tumors (ENGAGE-1) by Postel-Vinay, Sophie, Lam, Vincent K., Ros, Willeke, Bauer, Todd M., Hansen, Aaron R., Cho, Daniel C., Hodi, F. Stephen, Schellens, Jan H.M., Litton, Jennifer K., Aspeslagh, Sandrine, Autio, Karen A., Opdam, Frans L., McKean, Meredith, Somaiah, Neeta, Champiat, Stephane, Altan, Mehmet, Spreafico, Anna, Rahma, Osama, Paul, Elaine M., Ahlers, Christoph M., Zhou, Helen, Struemper, Herbert, Gorman, Shelby A., Watmuff, Maura, Yablonski, Kaitlin M., Yanamandra, Niranjan, Chisamore, Michael J., Schmidt, Emmett V., Hoos, Axel, Marabelle, Aurélien, Weber, Jeffrey S., Heymach, John V.

    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  3. 3
    Abstract CT027: A phase I, open-label study of GSK3174998 administered alone and in combination with pembrolizumab in patients (pts) with selected advanced solid tumors (ENGAGE-1)

    Abstract CT027: A phase I, open-label study of GSK3174998 administered alone and in combination with pembrolizumab in patients (pts) with selected advanced solid tumors (ENGAGE-1) by Infante, Jeffrey, Ahlers, Christoph M., Hodi, F Stephen, Postel-Vinay, Sopie, Schellens, Jan HM, Heymach, John V., Autio, Karen, Barnette, Mary, Struemper, Herbert, Watmuff, Maura, Paul, Elaine M., Kaufman, David R., Weber, Jeffrey S., Hoos, Axel

    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:

Search Tools: